| Co-Investigator(Kenkyū-buntansha) |
TAKATA Masaru Kochi Medical School, Faculty of Medicine, Assistant Professor, 医学部, 講師 (80136374)
SHEN Yuan Kochi Medical School, Faculty of Medicine, Research Associate, 医学部, 助手 (50294830)
HAMASATO Shinji Kochi Medical School, Faculty of Medicine, Research Associate, 医学部, 助手 (60228533)
ジュストリシィ ロザリオ カタニア大学, 医学部, 教授
マルチェリーノ ルチオ・ ローマ大学, 医学部, 教授
|
|---|
| Budget Amount *help |
¥6,700,000 (Direct Cost: ¥6,700,000)
Fiscal Year 1999: ¥2,700,000 (Direct Cost: ¥2,700,000)
Fiscal Year 1998: ¥4,000,000 (Direct Cost: ¥4,000,000)
|
|---|
| Research Abstract |
The head investigator (Prof. Shigeyoshi Fujimoto) and his research group have been developing cytotoxic T lymphocyte (CTL) therapy against cancer as a cancer specific immunotherapy. Since our results of CTL therapy were reported in International symposiums, International Cancer Congresses, and International Immunology Congresses, many medical investigators were interested in our CTL therapy, and offered research collaboration to us. CTL therapy is essentially based on the procedure of in vitro CIL induction in peripheral mononuclear cells of cancer patients stimulated by attenuated autologous cancer cells in 7 day stimulation culture. Once CTL is activated the activated mononuclear cells including activated CTL are given intravenously once a week repeatedly, resulted in tumor dormancy. We have been collaborating with Prof. Lucio R. Marcellino's research group in Department of Oncosurgery, Faculty of medicine, University of Rome "La Sapienza" for application of CTL therapy to various ty
… More
pe of malignant tumors since 1995. From the beginning of April, 1998 to the end of March, 2000, we performed the following activities using this grant. (1) From October 18 to November 2, 1998, the head investigator and Dr. Y. Shen visited Prof. Marcellino of Department of Oncosurgery, Univ. Rome "La Sapienza" and presented our new basic development concerning CTL therapy to improve efficacy of the therapy in various associated hospitals in Rome, Velletri, Civitavecchia and San Marino Republic. A major point of the new development was that we found Th2 type CD4 helper T cell subset capable of rejecting syngeneic tumor in tumor growing mice. We are going to apply this finding for human system. During our stay in Rome, we participated and presented in an International Symposium on "Predictive Oncology and Therapy" which was held in Nice, France from October 24-28, 1998. (2)Fchruary, 1999 we invited Prof. Marcellino, Dr. G. Ghironzi (Director of San Marino state hospital), and Dr. R. Nonni (Chief of Gastrointestinal Department in a villa Maria group hospital at Largo) to the 3ィイD1rdィエD1 annual meeting of "Cancer Specific Immunotherapy" in Tokyo organized by the head investigator and to our lab, Department of Immunology, Kochi Medical School to inspect our facility for CTL therapy. (3)From October 23-27ィイD1thィエD1, 1999, the head investigator, Dr. Y. Shen, and Dr. T. Fu participated in the International Immunology Congress held in Shanghai to present our new data (4)From November 11-21, 1999, the head investigator visited Prof. Marcellino in Rome and several villa Maria Group hospitals at Ravenna to exchange our latest information and discuss a new direction of our collaborative research work concerning CTL therapy. (5)November 11-13, 1999, we invited two young oncologists in the Cancer Institute of Catholic University of Rome by a recommendation of Prof. Marcellino to the 4th annual meeting of "Cancer Specific Immunotherapy" in Tokyo organized by the head of investigator to exchange scientific medical information of cancer immunotherapy. Less
|
